1. Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease.

    Movement Disorders 31(7):1012 (2016) PMID 27062301 PMCID PMC4931950

    Quantitative EEG features have been identified as surrogates and predictors of cognitive decline/dementia, a common feature of progressive PD. The biochemical correlates for altered quantitative EEG features are unknown. Our primary objective was to test the hypothesis that quantitative EEG meas...
  2. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study.

    Journal of nuclear medicine : official publicat... 57(6):900 (2016) PMID 26823561

    Training for accurate image interpretation is essential for the clinical use of β-amyloid PET imaging, but the role of interpreter training and the accuracy of the algorithm for routine visual assessment of florbetaben PET scans are unclear. The aim of this study was to test the robustness of th...
  3. Graph theory network function in Parkinson's disease assessed with electroencephalography.

    Clinical Neurophysiology 127(5):2228 (2016) PMID 27072094

    To determine what differences exist in graph theory network measures derived from electroencephalography (EEG), between Parkinson's disease (PD) patients who are cognitively normal (PD-CN) and matched healthy controls; and between PD-CN and PD dementia (PD-D). EEG recordings were analyzed via gr...
  4. Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.

    Neurology Neuroimmunology & Neuroinflammation 3(1):e193 (2016) PMID 26848485 PMCID PMC4733150

    To identify a panel of peripheral inflammatory/immune mediators that could discriminate Parkinson disease with dementia (PDD) from Parkinson disease (PD) without dementia. Plasma samples from 52 patients with PD and 22 patients with PDD were prepared from freshly collected blood following an ins...
  5. Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders.

    Journal of Parkinson's Disease 6(1):153 (2016) PMID 26756744

    Clinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy. Previously, we reported, from both autopsy and needle biopsy, a high prevalence of submandibular g...
  6. Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases.

    Journal of Neuropathology & Experimental Neurology 74(9):934 (2015) PMID 26230581 PMCID PMC4543436

    The clinical diagnosis and classification of neurodegenerative diseases based on clinical examination or available biomarkers are currently insufficiently accurate. Although histologic examination is considered the gold standard for diagnosis, brain biopsies have been avoided because of the high...
  7. REM sleep behavior disorder and neuropathology in Parkinson's disease.

    Movement Disorders 30(10):1413 (2015) PMID 26265105

    Rapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson's disease (PD) is associated with differences in clinical phenotype, including dementia, autonomic loss, and gait dysfunction. The pathological basis for this remains unclear. Parkinson's disease subjects in a longitudinal clini...
  8. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.

    Neuropathology 35(4):354 (2015) PMID 25619230 PMCID PMC4593391

    The Brain and Body Donation Program (BBDP) at Banner Sun Health Research Institute (http://www.brainandbodydonationprogram.org) started in 1987 with brain-only donations and currently has banked more than 1600 brains. More than 430 whole-body donations have been received since this service was c...
  9. Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

    Alzheimer's & Dementia 11(8):994 (2015) PMID 25849033 PMCID PMC4543530

    Down syndrome (DS) is associated with amyloid b (Ab) deposition. We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2),...
  10. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

    Alzheimer's & Dementia 11(8):964 (2015) PMID 25824567

    Evaluation of brain β-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Open-label, nonrandomized, multicenter, phase 3 study to validate the (18)F-labeled β-amyloid tracer florbetaben by comparing in vivo PET imaging...
  11. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.

    Expert Opinion on Investigational Drugs 24(3):393 (2015) PMID 25586103

    Reduction in the deposition of amyloid β (Aβ) has been the primary target for Alzheimer's disease (AD) therapeutics recently, but in clinical trials this approach has generally been unsuccessful. A common feature of AD pathology is a complex inflammatory component that could be a target for trea...
  12. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

    JAMA Neurology 72(3):287 (2015) PMID 25622185

    In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to dete...
  13. Clinical characterization of mild cognitive impairment as a prodrome to dementia with Lewy bodies.

    American Journal of Alzheimer's Disease and Oth... 30(2):173 (2015) PMID 25013117 PMCID PMC4593401

    Limited information regarding the specificity of mild cognitive impairment (MCI) as it relates to dementia with Lewy bodies (DLB) exists. Here, we summarize the clinical phenotype of MCI in clinically suspect DLB. Ten patients with a primary diagnosis of MCI and secondary diagnoses of DLB were i...
  14. Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.

    Alzheimer's Research & Therapy 7(1):1 (2015) PMID 26584966 PMCID PMC4652427

    Longitudinal assessment of cognitive decline in amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) often involves the use of both informant-based and objective cognitive assessments. As efforts have focused on identifying individuals in pre-clinical stages, instruments that a...
  15. Longitudinal EEG changes correlate with cognitive measure deterioration in Parkinson's disease.

    Journal of Parkinson's Disease 5(1):117 (2015) PMID 25420672

    QEEG could provide physiological biomarkers for changes over time in Parkinson's disease (PD) cognitive decline if they track with longitudinal neuropsychological performance. Our aim was to correlate longitudinal changes in frequency domain quantitative electroencephalography (QEEG) measures wi...
  16. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment.

    BMC Neurology 15:146 (2015) PMID 26289075 PMCID PMC4545878

    Although there are studies investigating the pathologic origins of mild cognitive impairment (MCI), they have revolved around comparisons to normal elderly individuals or those with Alzheimer's disease (AD) or other dementias. There are few studies directly comparing the comprehensive neuropatho...
  17. Neuropsychological Correlates of the Alzheimer's Questionnaire.

    Journal of Alzheimer's Disease 46(2):389 (2015) PMID 25737045

    Informant-based assessments of cognition and function are commonly used to differentiate individuals with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) from those who are cognitively normal. However, determining the extent to which informant-based measures correlate to o...
  18. Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain.

    Neurology and Therapy 3(2):79 (2014) PMID 26000224 PMCID PMC4386430

    Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting the elderly. Current clinical diagnostic tools are often ineffective in accurately diagnosing AD. However, new advances in diagnostic imaging, particularly positron emission tomography (PET) amyloid imaging, have show...
  19. Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease.

    Parkinsonism & Related Disorders 20(11):1260 (2014) PMID 25172126 PMCID PMC4835172

    Olfactory dysfunction in Parkinson's disease (PD) is well-established and may represent one of the earliest signs of the disease. The objective of this study was to evaluate the relationship of olfactory dysfunction, using the University of Pennsylvania Smell Identification Test (UPSIT), to clin...
  20. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease.

    Neurobiology of Aging 35(9):1961 (2014) PMID 24786631 PMCID PMC4067010

    Mild cognitive impairment (MCI) represents a cognitive state intermediate between normal aging and early Alzheimer's disease (AD). To investigate if the molecular signature of MCI parallels the clinical picture, we use microarrays to extensively profile gene expression in 4 cortical brain region...